<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is one of the most common and deadly <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in the world </plain></SENT>
<SENT sid="1" pm="."><plain>Most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e> are initiated by aberrant activation of the Wnt/ß-catenin signaling pathway </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the advances in its early diagnosis, optimized surgical approaches, and chemotherapies, the clinical management of advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> requires effective adjuvant agents </plain></SENT>
<SENT sid="3" pm="."><plain>Ginsenoside Rg3 is a single compound isolated from American ginseng (Panax quinquefolius L., Araliaceae) and Asian ginseng (Panax ginseng C </plain></SENT>
<SENT sid="4" pm="."><plain>A </plain></SENT>
<SENT sid="5" pm="."><plain>Meyer) </plain></SENT>
<SENT sid="6" pm="."><plain>We investigated the anticancer activity of Rg3 on <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells and its potential molecular mechanism behind Rg3's anticancer activity </plain></SENT>
<SENT sid="7" pm="."><plain>We found that Rg3 inhibits cell proliferation and viability of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in vitro </plain></SENT>
<SENT sid="8" pm="."><plain>This inhibitory effect of Rg3 is, at least in part, mediated by blocking nuclear translocation of the ß-catenin protein and hence inhibiting ß-catenin/Tcf transcriptional activity </plain></SENT>
<SENT sid="9" pm="."><plain>Allelic deletion of the oncogenic ß-catenin in HCT116 cells renders the cells more sensitive to Rg3-induced growth inhibition </plain></SENT>
<SENT sid="10" pm="."><plain>Using the xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model of human <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, we have demonstrated that Rg3 effectively inhibits the growth of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> derived from the human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line HCT116 </plain></SENT>
<SENT sid="11" pm="."><plain>Histologic examination revealed that Rg3 inhibits <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell proliferation, decreases PNCA expression and diminishes nuclear staining intensity of ß-catenin </plain></SENT>
<SENT sid="12" pm="."><plain>Taken together, our results strongly suggest that the anticancer activity of Rg3 may be in part caused by blocking the nuclear translocation of ß-catenin in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
<SENT sid="13" pm="."><plain>This line of investigation may lead to the development of novel therapies in which Rg3 can be used as an effective adjuvant agent for the clinical management of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
</text></document>